Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
The appropriateness of prescribing antibiotics in primary health care in Europe with respect to antibiotic resistance (APRES)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Netherlands,United Kingdom,Netherlands,Belgium,United Kingdom,France,Croatia,Austria,United Kingdom,Austria,Spain,Hungary,Belgium,Sweden
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-10-01
End date: 2014-03-31
Duration (months): 54.0
Total project cost (EUR): 3632363.38
EU funding (EUR): 2809511.0
Participants: 14
Project status: CLOSED

The APRES project aims at providing information and recommendations on the appropriateness of prescribing antibiotics in primary care. The appropriateness of prescribing antibiotics is the extent to which the pattern of prescribed antibiotics is congruent with the antibiotic resistance pattern of bacteria. More than 90% of antibiotics in Europe is prescribed to non-hospitalized patients, but existing information on the antibiotic resistance pattern is exclusively based on samples from hospitalized patients. Guidelines for prescribing antibiotics to outpatients cannot be based on empirical evidence about antibiotic resistance of bacteria circulating in the community because this evidence is lacking. The APRES project contains 4 work packages. WP1 includes a) a systematic review on the relationship between outpatient consumption of antibiotics and patterns of antibiotic resistance of pathogens circulating in the community; b) the establishment of a database of information sources and databases in nine European countries on outpatient consumption of antibiotics and antibiotic resistance patterns of pathogens circulating in the community. In WP2 the antibiotic resistance pattern of S. aureus and S. pneumoniae will be established in nine European countries, based on samples from healthy persons consulting in primary care practices participating in nationally representative networks. In WP3 we will establish the 5-year pattern of prescribed antibiotics the same practices and its variation between nine European countries. The data will be retrieved from electronic medical records in the same primary care practices. WP4 includes the integrative analyses by linking the antibiotic prescribing data with the antibiotic resistance patterns obtained in the same practices to establish the appropriateness of prescribing antibiotics. On the basis of these results, country specific guidelines will be formulated for appropriate prescribing of antibiotics.

Keywords: appropriateness antibiotics primary care antibiotic resistance
High throughput molecular diagnostics in individual patients for genetic diseases with heterogeneous clinical presentation (TECHGENE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Netherlands,Belgium,Czechia,Spain,Italy,Germany,Netherlands,Italy,France,United Kingdom,Estonia
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-02-01
End date: 2012-01-31
Duration (months): 36.0
Total project cost (EUR): 3856680.0
EU funding (EUR): 2997010.0
Participants: 12
Project status: CLOSED

Since the sequencing of the human genome has been completed the demand for genetic analysis in the human health care system is drastically increasing, and the extension of molecular genetic diagnostics is urgently needed. However, the majority of genetic diseases is molecularly and clinically highly heterogeneous, and until recently the available techniques lacked the required capacity to analyze several genes in parallel. The recently introduced high-throughput whole genome sequencing (WGS) technology now offers the unique opportunity to extend molecular genetic analysis by introducing these techniques, and develop taylormade medical resequencing approaches for molecular genetic diagnosis of heterogeneous disorders. This project aims to deliver crucial innovations leading to these approaches, and to deliver a proof-of-principle for its implementation in selected model disorders. The model disorders have been selected with increasing genetic complexity, and represent the majority of non-multifactorial genetic disorders. The current momentum to perform these innovations by a European consortium of clinical genetic diagnostic laboratories and research laboratories and industrial stakeholders will lead to a front-running position of European laboratories and small and medium enterprises (SMEs) in this field. The consortium putting forward this proposal consists of leading scientists and established laboratories providing cutting edge knowledge with respect to quality management aspects, ethical and societal issues, and cost effectiveness issues. This is the only approach that will warrant the development of diagnostic tools designed to restrict genetic testing to relevant medical factors. For European SMEs this proposal offers the opportunity to identify niches in the steadily increasing molecular genetic market. A specially designed training programme will take care of rapid dissemination of the acquired knowledge and tools across Europe.

Keywords: molecular diagnosis high throughput whole genome sequencing medical resequencing genetic heterogeneity quality management validation cost effectiveness analysis ethical issues data analysis
Understanding inflammation-associated tumorigenesis for the rational design of novel anti-cancer therapeutic strategies. (INFLA-CARE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Greece,Austria,Israel,Greece,Italy,France,United Kingdom,Germany,Spain,United Kingdom,Germany,United Kingdom,Croatia,United Kingdom,Czechia,United Kingdom,Spain
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2013-06-30
Duration (months): 54.0
Total project cost (EUR): 16211687.27
EU funding (EUR): 11999889.0
Participants: 22
Project status: CLOSED

Epidemiological and experimental evidence supports a link between chronic inflammation and cancer and indicates a role for inflammatory cells in the initiation, progression and metastasis of malignancy. The objective of the collaborative integrated project INFLA-CARE is to structure a European collective of scientific and technological excellence in the field of ‘Inflammation & Cancer’ which will capitalise on the available expertise and develop effective anti-inflammatory strategies and novel agents for cancer prevention and treatment. The project will specifically seek to identify molecular and cellular targets for cancer therapy through the development and systematic study of state-of-the-art pre-clinical models of inflammation-driven cancer. By mobilising the outstanding research experience and technological capacities of the network participants, the program will accelerate the translation of knowledge obtained by basic research into new diagnostic and therapeutic strategies which will be used for the detection, prevention and improved management of several types of human cancer. INFLA-CARE will also ensure spreading of scientific excellence and dissemination of knowledge beyond the network, by encouraging innovation and transfer of knowledge and by raising public understanding of scientific and health issues. The impact of the program is therefore expected to be multi-dimensional, namely scientific, educational and innovation-related, enhancing European competitiveness and addressing major scientific issues and societal needs.

Keywords: cancer,inflammation,therapy,disease models
Development of a European Implementation Score for measuring implementation of research into healthcare practice using vascular disease as an example (EIS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: United Kingdom,Italy,Sweden,Germany,Germany,Germany
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-04-01
End date: 2013-09-30
Duration (months): 54.0
Total project cost (EUR): 3602429.47
EU funding (EUR): 2767922.0
Participants: 8
Project status: CLOSED

This collaborative project will develop a European methodology to assess the implementation of research evidence into practice (the European Implementation Score (EIS)), in primary, secondary and specialist care from the perspectives of different target groups (users and carers, voluntary organisations, range of health and social care professionals and health policy makers). The EIS will measure how well new knowledge is implemented into clinical practice in Europe. The EIS will address implementation of research knowledge at different levels of the health care system (micro-, meso- and macro-level) and in different health care settings (e.g. primary care, hospital, specialised care). The focus of the project will be in stroke because of the emerging new evidence of effective new treatments available and because of the national initiatives and governmental policies in this area. We will test the transferability of the develop methods using coronary heart disease as another vascular disease example. General recommendations for measuring effective implementation of research results will be developed from the perspectives of users, health care professionals and health policy, hence widening the theoretical framework for effective implementation from a focus on patients and professionals alone. The different components of the EIS will be refined according to their ability to predict successful implementation of evidence based stroke care in different settings in Europe. The identification of factors determining effective implementation will be data driven, analysing available data from national audits and population-based registers. The EIS will benchmark the current status of implementation of research results in different health care settings at different levels of the health care system and will inform health policy of a possible set of processes required for closing the research/practice gap.

Keywords: implementation,score,micro,meso,macro level,user perspective,vascular disease,policy recommendations
Development of a DNA vaccine for visceral leishmaniasis (LEISHDNAVAX)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Germany,India,Tunisia,Israel,Switzerland
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2012-06-30
Duration (months): 42.0
Total project cost (EUR): 4096654.4
EU funding (EUR): 2989200.0
Participants: 8
Project status: CLOSED

This project will focus on the preclinical development of a DNA vaccine for human visceral leishmaniasis. The project is based upon the DNA vaccine technology and immunomodulators developed at Mologen AG (Berlin, Germany), which are in clinical development for cancer and 3-5 known antigens that already have demonstrated profiles of protection in animal models of leishmaniasis. Antigens will be selected on the basis of preset criteria to assure protection in high proportion of target populations and against many different species of Leishmania. In vitro and in vivo models will be used to evaluate the prophylactic and therapeutic efficacy of the DNA vehicle with selected antigens alone and in combination with and without immunomodulator. Full toxicology studies will be performed on selected candidate vaccines. Training in preclinical development and clinical trials (ICH-GCP) are an important part of the proposal. Sites will be selected and ready to initiate clinical trials at the end of this project (3 years).

Keywords: visceral leishmaniasis dna vaccine
Platform for the Harmonization of Vaccine Adjuvant Testing (PHARVAT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Coordination and support actions
Countries involved: Netherlands,Switzerland,Germany
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-11-01
End date: 2011-10-31
Duration (months): 24.0
Total project cost (EUR): 334018.16
EU funding (EUR): 300000.0
Participants: 3
Project status: CLOSED

Adjuvants are critical to the quality and magnitude of immune responses generated by PRD vaccines. However, vaccine development is hampered by lack of access to appropriate adjuvants. This is partly because adjuvants are developed in many organizations, with individual models and protocols that have been established independently. The resulting data on adjuvants are only rarely directly comparable and exploitable in other vaccine studies. The project objective is to determine the laboratory tests that can be used to harmonize pre-clinical determination of vaccine adjuvant activity and safety throughout Europe, including new-member countries, and in the developing world, based on an in-depth survey and analysis of best practice employed by industry and other stakeholders in adjuvant R&D. A database of survey results will be analysed by experts and used to establish the tests that are considered most useful by stakeholders to characterize adjuvant activity and safety. Dissemination of results will occur through a workshop organized with WHO for stakeholders (including key international organizations representatives), publications and websites. The tests will allow the activities of adjuvants to be compared directly and will therefore contribute a major advantage in the selection of adjuvants to be included in PRD vaccine development programmes.

Keywords: prd vaccine adjuvants,survey best practice,testing harmonization,adjuvant testing platform,dissemination
Population age structure and age structure modification via Wolbachia in Anopheles gambiae (ANOPOPAGE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Greece,Burkina Faso,France,Australia,Kenya
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-02-01
End date: 2012-07-31
Duration (months): 42.0
Total project cost (EUR): 1355286.56
EU funding (EUR): 1000000.0
Participants: 6
Project status: CLOSED

One of the most critical factors contributing to the vectorial capacity of malaria vector mosquitoes is the mean age attained by adult females, because after picking up the Plasmodium parasite there is a lengthy incubation period before transmission can occur. A virulent strain of the endosymbiotic bacterium Wolbachia called wMelPop reduces adult lifespan in its native Drosophila host, and has recently been shown to do the same following transfer into Aedes mosquitoes. We will examine its potential as a novel malaria control tool by creating and characterizing Anopheles cell lines containing wMelPop, and purifying and transferring it into An. gambiae by microinjection. We will then characterize the cytoplasmic incompatibility phenotype by which Wolbachia spreads itself, virulence (lifespan shortening effects), maternal transmission rates, and tissue distribution of introduced Wolbachia, together with analyses of mosquito gene expression using microarrays. Development of a molecular age estimation assay for the An. gambiae complex will be undertaken by adapting a new quantitative RT-PCR method for use in An. gambiae. We will then set up a greenhouse population of a member of the An. gambiae complex in Kenya that is viable over multiple generations, release marked mosquitoes to calibrate the molecular age estimation assays under semi-field conditions, and compare age structure between greenhouse and wild populations. In Burkina Faso we will estimate population age structure in the An. gambiae complex at 3 field sites, in different seasons and with / without insecticide treated net use. Liaison will take place with government institutions and local communities on regulatory issues and desirability of future Wolbachia-based trials in both countries. We will also build a suite of mathematical models to allow the analysis of different interventions that affect adult mosquito longevity, and incorporate the dynamics of Wolbachia spread in an age-structured population.

Keywords: malaria anopheles mosquito wolbachia plasmodium virulence vectorial capacity gene expression mathematical model
EuropeaN Energy balance Research to prevent excessive weight Gain among Youth (ENERGY)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Netherlands,Belgium,Norway,Germany,Denmark,Spain,Greece,United Kingdom,Hungary,Switzerland,Australia,United Kingdom,Slovenia
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-02-01
End date: 2012-07-31
Duration (months): 42.0
Total project cost (EUR): 3865339.6
EU funding (EUR): 2872588.0
Participants: 16
Project status: CLOSED

Objective: The ENERGY proposal addresses HEALTH-2007-3.3-1: Promoting healthy behaviour in children and adolescents. It will be specifically focussed on promoting health behaviours that contribute to prevention of overweight and obesity among children and adolescents. Strategy: The project will use a multidisciplinary analysis of determinants and intervention schemes on extrinsic and intrinsic factors determining specific nutrition and physical activity behaviours in children and adolescents in different populations and regions. This in order to develop an evidence and theory-based new scheme to prevent unnecessary weight gain among youth in transition from childhood to adolescence. The new intervention scheme will be school-based and family-involved, thus combining a key intervention setting (schools) with a key behavioural determining environment (family). This new scheme will be validated for improved capacity to encourage and sustain healthful eating and physical activity behaviours, and the results will be disseminated among key stakeholders including researchers, policy makers and the general population. Methods: In 10 work packages systematic reviews, secondary analyses of existing and accessible data sets, focus group research, survey and community-trial evaluation research among schoolchildren, parents and school staff will be conducted according to state-of-the art methodology guided by an established and approved research quality handbook. Consortium: The ENERGY project consortium spans the necessary multidisciplinary variety of experts such as public health experts, epidemiologists, nutritionists, physical activity experts, health promotion experts, paediatricians, psychologists, economists, totalling 14 partners, from 11 countries representing all regions of Europe. The consortium has ample experience in conducting and coordinating multi-centre international research as well as international dissemination to all relevant stakeholders.

Keywords: health behaviour,schoolchildren,adolescents,intervention,overweight,school environment,family environment
Clinical decision making and outcome in routine care for people with severe mental illness (CEDAR)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Germany,United Kingdom,Italy,Hungary,Denmark,Switzerland
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-04-01
End date: 2012-09-30
Duration (months): 42.0
Total project cost (EUR): 2252734.08
EU funding (EUR): 1763856.0
Participants: 6
Project status: CLOSED

Background: A considerable amount of research has been conducted on clinical decision making (CDM) in short-term physical conditions. However, there is a lack of knowledge on CDM and its outcome in long-term illnesses, especially in care for people with severe mental illness. Thus, this project entitled "Clinical decision making and outcome in routine care for people with severe mental illness" (CEDAR) is proposed by participants in six European countries (Denmark, Germany, Hungary, Italy, Switzerland and UK). Methods: First, CEDAR will establish a methodology to assess CDM in people with severe mental illness. Specific instruments will be developed (and psychometric properties established) to measure CDM style, key elements of CDM in routine care, as well as CDM involvement and satisfaction from patient and therapist perspectives. Second, these instruments will be put to use in a multi-national prospective observational study (monthly assessments during a one-year observation period; N = 540). This study will investigate the immediate, short- and long-term effect of CDM on crucial dimensions of clinical outcome (symptom level, quality of life, needs) by taking into account significant variables moderating the relationship between CDM and outcome. Expected results/impact: The results of this study will make possible to delineate quality indicators of CDM, as well as to specify prime areas for further improvement. Ingredients of best practice in CDM in the routine care for people with severe mental illness will be extracted and recommendations formulated. With its explicit focus on the patient role in CDM, CEDAR will also contribute to strengthening the service user perspective. Beyond dissemination of results in scientific journals, a number of steps to ensure swift transfer of the results to routine practice are proposed. Thus, this project will substantially add to improving the practice of CDM in mental health care across Europe.

Keywords: clinical decision making,severe mental illness,clinical outcome,routine care